Kalvista Pharmaceuticals (NASDAQ:KALV) Downgraded by BidaskClub to “Strong Sell”

BidaskClub downgraded shares of Kalvista Pharmaceuticals (NASDAQ:KALV) from a sell rating to a strong sell rating in a research note released on Tuesday, BidAskClub reports.

Several other equities analysts also recently issued reports on the stock. Svb Leerink began coverage on shares of Kalvista Pharmaceuticals in a report on Monday, July 29th. They set an outperform rating and a $31.00 price objective on the stock. Zacks Investment Research downgraded shares of Kalvista Pharmaceuticals from a buy rating to a sell rating in a report on Wednesday, July 17th. Leerink Swann began coverage on shares of Kalvista Pharmaceuticals in a report on Monday, July 29th. They set an outperform rating and a $31.00 price objective on the stock. ValuEngine downgraded shares of Kalvista Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 2nd. Finally, Roth Capital reissued a buy rating on shares of Kalvista Pharmaceuticals in a research note on Tuesday, May 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company has an average rating of Buy and an average target price of $29.86.

KALV opened at $15.79 on Tuesday. The stock has a market capitalization of $281.86 million, a P/E ratio of -11.44 and a beta of 2.10. Kalvista Pharmaceuticals has a 52-week low of $10.30 and a 52-week high of $34.92. The firm’s fifty day moving average is $18.61.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Monday, July 15th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.07). The company had revenue of $2.93 million for the quarter, compared to analysts’ expectations of $3.64 million. Kalvista Pharmaceuticals had a negative net margin of 127.20% and a negative return on equity of 24.57%. Analysts forecast that Kalvista Pharmaceuticals will post -2.67 earnings per share for the current year.

In other Kalvista Pharmaceuticals news, insider Edward P. Feener sold 3,300 shares of Kalvista Pharmaceuticals stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $18.62, for a total transaction of $61,446.00. Following the transaction, the insider now directly owns 98,634 shares of the company’s stock, valued at $1,836,565.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Albert Cha bought 56,367 shares of Kalvista Pharmaceuticals stock in a transaction on Monday, July 29th. The shares were purchased at an average cost of $16.99 per share, for a total transaction of $957,675.33. The disclosure for this purchase can be found here. Over the last three months, insiders bought 145,427 shares of company stock worth $2,515,550. Insiders own 38.40% of the company’s stock.

A number of hedge funds have recently modified their holdings of KALV. FMR LLC purchased a new position in Kalvista Pharmaceuticals during the first quarter worth about $21,036,000. Marshall Wace LLP purchased a new position in Kalvista Pharmaceuticals during the first quarter worth about $843,000. Laurion Capital Management LP raised its stake in Kalvista Pharmaceuticals by 94.9% during the first quarter. Laurion Capital Management LP now owns 58,871 shares of the specialty pharmaceutical company’s stock worth $1,685,000 after purchasing an additional 28,670 shares during the period. BlackRock Inc. raised its stake in Kalvista Pharmaceuticals by 133.5% during the fourth quarter. BlackRock Inc. now owns 45,078 shares of the specialty pharmaceutical company’s stock worth $891,000 after purchasing an additional 25,769 shares during the period. Finally, Geode Capital Management LLC raised its stake in Kalvista Pharmaceuticals by 30.6% during the fourth quarter. Geode Capital Management LLC now owns 83,881 shares of the specialty pharmaceutical company’s stock worth $1,656,000 after purchasing an additional 19,636 shares during the period. 80.01% of the stock is currently owned by institutional investors.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also: How dollar cost averaging works

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.